<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2005</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2026-22-1-76-81</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL NOTES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical case of treatment of a patient with germ cell tumor in the intensive care unit</article-title><trans-title-group xml:lang="ru"><trans-title>Клинический случай лечения пациента с герминогенной опухолью в условиях реанимационного отделения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1843-8743</contrib-id><name-alternatives><name xml:lang="en"><surname>Arkova</surname><given-names>S. A.</given-names></name><name xml:lang="ru"><surname>Арькова</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3532-6476</contrib-id><name-alternatives><name xml:lang="en"><surname>Golubev</surname><given-names>Pavel V.</given-names></name><name xml:lang="ru"><surname>Голубев</surname><given-names>Павел Вячеславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-2856-5176</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuzmina</surname><given-names>E. S.</given-names></name><name xml:lang="ru"><surname>Кузьмина</surname><given-names>Е. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0874-0217</contrib-id><name-alternatives><name xml:lang="en"><surname>Suryakhina</surname><given-names>Ya. I.</given-names></name><name xml:lang="ru"><surname>Суряхина</surname><given-names>Я. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7351-2662</contrib-id><name-alternatives><name xml:lang="en"><surname>Banova</surname><given-names>Zh. I.</given-names></name><name xml:lang="ru"><surname>Банова</surname><given-names>Ж. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-9658-3586</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuzmin</surname><given-names>V. M.</given-names></name><name xml:lang="ru"><surname>Кузьмин</surname><given-names>В. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3250-9720</contrib-id><name-alternatives><name xml:lang="en"><surname>Gromov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Громов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>golubev194@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">S.S. Yudin City Clinical Hospital, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ г. Москвы «Городская клиническая больница им. С.С. Юдина Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-07-10" publication-format="electronic"><day>10</day><month>07</month><year>2026</year></pub-date><volume>22</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>76</fpage><lpage>81</lpage><history><date date-type="received" iso-8601-date="2026-01-07"><day>07</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-03-19"><day>19</day><month>03</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, АБВ-пресс</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/2005">https://oncourology.abvpress.ru/oncur/article/view/2005</self-uri><abstract xml:lang="en"><p>Testicular germ cell tumors are the most common malignant neoplasms in young men. Despite overall high curability, some patients present with advanced disease and critical general condition caused by extensive tumor burden. We report a clinical case of a 28-year-old male with bilateral testicular germ cell tumor (embryonal carcinoma) complicated by metastatic involvement of the lungs, liver, lymph nodes, and inferior vena cava thrombosis extending into the right atrium. The patient was admitted to the intensive care unit due to severe respiratory failure and required mechanical ventilation. Cisplatin monotherapy was initiated, followed by escalation to the paclitaxel–ifosfamide–cisplatin (TIP) regimen with granulocyte-macrophage colony-stimulating factors prophylaxis. Despite the initial critical condition, significant clinical improvement was achieved, including normalization of tumor markers and near-complete response according to CT imaging after four cycles of chemotherapy. This case highlights that systemic chemotherapy can and should be administered even in intensive care settings, including mechanical ventilation, and may lead to clinical recovery and tumor regression.</p></abstract><trans-abstract xml:lang="ru"><p>Герминогенные опухоли яичка представляют собой наиболее распространенные злокачественные новообразования у мужчин молодого возраста. Несмотря на высокую излечиваемость, часть пациентов обращаются в крайне тяжелом состоянии, обусловленном распространенным опухолевым процессом. В статье представлен клинический случай лечения 28-летнего пациента с билатеральной герминогенной опухолью яичка (эмбриональная карцинома), осложненной метастатическим поражением легких, печени и лимфатических узлов, а также тромбозом нижней полой вены с распространением в правое предсердие. В связи с дыхательной недостаточностью пациент находился в отделении реанимации на искусственной вентиляции легких. Инициировано лечение цисплатином в монорежиме, затем проведена эскалация терапии до схемы TIP (паклитаксел, ифосфамид, цисплатин) с профилактикой гранулоцитарно-макрофагальными колониестимулирующими факторами. Несмотря на критическое исходное состояние, отмечена положительная динамика: улучшение общего самочувствия, нормализация показателей онкомаркеров и почти полный ответ по данным компьютерной томографии после 4 курсов химиотерапии. Представленный случай подтверждает, что проведение системной терапии возможно и оправдано даже в условиях интенсивной терапии и искусственной вентиляции легких и может приводить к клиническому выздоровлению и регрессии опухоли.</p></trans-abstract><kwd-group xml:lang="en"><kwd>germ cell tumors</kwd><kwd>intensive care</kwd><kwd>paclitaxel</kwd><kwd>ifosfamide</kwd><kwd>cisplatin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>герминогенные опухоли</kwd><kwd>реанимация</kwd><kwd>паклитаксел</kwd><kwd>ифосфамид</kwd><kwd>цисплатин</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74(1):12–49. DOI: 10.3322/caac.21820</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Giona S. The Epidemiology of Testicular Cancer. In: Urologic Cancers. Chapter 9. Eds.: N. Barber, A. Ali. Brisbane (AU): Exon Publications, 2022.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63. DOI: 10.3322/caac.21834</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. 239 с. State of oncological care in Russia in 2022. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2023. 239 p. (In Russ.).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>McHugh D.J., Gleeson J.P., Feldman D.R. Testicular cancer in 2023: Current status and recent progress. CA Cancer J Clin 2024;74(2):167–86. DOI: 10.3322/caac.21819</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tateo V., Mollica V., Rizzo A. et al. Re: WHO Classification of Tumours, 5th edn. Vol. 8: Urinary and Male Genital Tumours. Eur Urol 2023;84(3):348–9. DOI: 10.1016/j.eururo.2023.04.030</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pang K.H., Alnajjar H.M., Muneer A. Diagnosis, treatment and survival from testicular cancer: real-world data from the national health service England 2013 and 2020. Clin Genitourin Cancer 2025;23(4):102367. DOI: 10.1016/j.clgc.2025.102367</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Grela K., Sobchynskyi M., Piȩtak M. et al. Salvage chemotherapy in the intensive care unit: a case report of successful treatment of a critically ill patient with metastatic testicular germ cell tumor. Front Med (Lausanne) 2025;12:1599413. DOI: 10.3389/fmed.2025.1599413</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Singla N., Bagrodia A., Baraban E. et al. Testicular germ cell tumors: a review. JAMA 2025;333(9):793–803. DOI: 10.1001/jama.2024.27122</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kier M.G., Lauritsen J., Mortensen M.S. et al. Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study. Eur Urol 2017;71(2):290–8. DOI: 10.1016/j.eururo.2016.09.015</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Briones J., Diaz P., Nicholson B.D. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed or refractory testicular cancer: a systematic review and meta-analysis. Front Oncol 2024;14:1437574. DOI: 10.3389/fonc.2024.1437574</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tryakin A., Fedyanin M., Bulanov A. et al. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status. J Cancer Res Clin Oncol 2018;144(9):1817–23. DOI: 10.1007/s00432-018-2695-4</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Матвеев В.Б., Волкова М.И., Гладков О.А. и др. Герминогенные опухоли у мужчин. Практические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли 2024;14(3s2):267–99. DOI: 10.18027/2224-5057-2024-14-3s2-1.2-11 Matveev V.B., Volkova M.I., Gladkov O.A. et al. Germ cell tumors in men. RUSSCO practical recommendations, part 1.2. Zlokachestvennyye opukholi = Malignant Tumours 2024;14(3s2): 267–99. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-1.2-11</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594–603. DOI: 10.1200/JCO.1997.15.2.594</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>De Wit R., Stoter G., Kaye S.B. et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15(5):1837–43. DOI: 10.1200/JCO.1997.15.5.1837</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Исраелян Э.Р., Трякин А.А., Румянцев А.А. и др. Режим паклитаксел, ифосфамид, цисплатин (TIP) при несеминомных герминогенных опухолях неблагоприятного и промежуточного прогноза с неудовлетворительным снижением уровня онкомаркеров: исследование II фазы. Злокачественные опухоли 2022;12(3):11–20. DOI: 10.18027/2224-5057-2022-12-3 Israelyan E.R., Tryakin A.A., Rumyantsev A.A. et al. Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study. Zlokachestvennyye opukholi = Malignant Tumours 2022;12(3):11–20. (In Russ.). DOI: 10.18027/2224-5057-2022-12-3</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Azambuja E., Fleck J.F., Batista R.G., Menna Barreto S.S. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther 2005;18(5):363–6. DOI: 10.1016/j.pupt.2005.01.007</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Mead G.M., Cullen M.H., Huddart R. et al.; MRC Testicular Tumour Working Party. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005;93(2):178–84. DOI: 10.1038/sj.bjc.6602682</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Chevreau C., Massard C., Flechon A. et al. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Med 2021;10(7):2250–8. DOI: 10.1002/cam4.3687</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kondagunta G.V., Bacik J., Donadio A. et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23(27):6549–55. DOI: 10.1200/JCO.2005.19.638</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Feldman D.R., Powles T. Salvage high-dose chemotherapy for germ cell tumors. Urol Oncol 2015;33(8):355–62. DOI: 10.1016/j.urolonc.2015.01.025</mixed-citation></ref></ref-list></back></article>
